Emergent BioSolutions (EBS) SVP reports 116-share tax-withholding disposition

Rhea-AI Filing Summary

Emergent BioSolutions Inc. senior vice president Paul Anthony Williams reported a small share disposition related to equity compensation. On the reported date, 116 shares of common stock were withheld at $8.15 per share to cover taxes triggered by the vesting and settlement of restricted stock units. This was an automatic tax-withholding transaction, not an open-market trade, and left Williams with a direct holding of 76,078 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Paul Anthony

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Products Business

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026	03/02/2026	F		116(1)	D	$8.15	76,078	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Emergent BioSolutions (EBS) report for Paul Anthony Williams?

Emergent BioSolutions reported that SVP Paul Anthony Williams had 116 common shares withheld to cover taxes from restricted stock unit vesting. This Form 4 transaction reflects a tax-withholding disposition, not an open-market purchase or sale of shares by the executive.

Was the Emergent BioSolutions (EBS) insider transaction an open-market sale of shares?

No, the transaction was not an open-market sale. The 116 Emergent BioSolutions common shares were withheld to satisfy tax obligations arising from the vesting and settlement of restricted stock units, as described in the footnote to the Form 4 filing.

How many Emergent BioSolutions (EBS) shares were involved in the tax-withholding transaction?

The Form 4 shows 116 shares of Emergent BioSolutions common stock were withheld at a price of $8.15 per share. These shares were used to pay taxes associated with the vesting and settlement of restricted stock units granted to SVP Paul Anthony Williams.

How many Emergent BioSolutions (EBS) shares does Paul Anthony Williams hold after the transaction?

After the tax-withholding disposition, Paul Anthony Williams directly holds 76,078 shares of Emergent BioSolutions common stock. The Form 4 specifies this post-transaction balance, reflecting his remaining direct equity stake following the restricted stock unit vesting event.

What does transaction code "F" mean in the Emergent BioSolutions (EBS) Form 4?

Transaction code "F" indicates a disposition of shares to pay an exercise price or tax liability. In this Emergent BioSolutions filing, 116 shares were withheld specifically to cover taxes from the vesting and settlement of restricted stock units granted to the reporting executive.

What role does Paul Anthony Williams hold at Emergent BioSolutions (EBS)?

Paul Anthony Williams is identified as an officer of Emergent BioSolutions with the title "SVP, Products Business." His Form 4 filing reports a routine tax-withholding disposition of 116 common shares tied to the vesting of restricted stock units awarded as compensation.